Amitiza Capsule, Gelatin Coated
Product Images NDC 64764-080

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Amitiza (NDC 64764-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Amitiza 01)

FDA Label Image

Principal Display Panel (8 mcg Capsule Bottle Label)

The text seems to be a description of a medication called "AMITIZA®". It comes in a package of 60 capsules with a strength of 8mcg. The packaging also contains warning about not chewing or breaking the capsules. There is also a reference to a prescribing information leaflet included in the package. The medication is marketed by Sucampo Pharma Americas LLC and Takeda Pharmaceuticals America Inc. The active ingredient is made in Japan and encapsulated in the United States. The last line is not clear and seems to be a mix of characters from different languages.*

FDA Label Image

Principal Display Panel (24 mcg Capsule Bottle Label)

Amitiza is a medication available in capsule form. The capsules contain 24 mcg of lubiprostone and are meant to be swallowed whole, not chewed or broken apart. The medication is only available through prescription and should be dispensed in a light-resistant container. The package contains 60 capsules. The manufacturer is Sucampo Pharmaceuticals Americas LLC located in Bedminster, NJ 07921 and Takeda Pharmaceuticals America, Inc. located in Lexington, WA 02621. The medication is encapsulated in the United States.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.